© 2024 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY · WNPR
WPKT · WRLI-FM · WEDW-FM · Public Files Contact
ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

UConn Researchers Study High-Dose Flu Vaccine for Elderly

Government of Albert
/
Creative Commons
Some of the elderly may do better with a high-dose flu vaccine. Some may do just as well with a normal one.

Researchers at the University of Connecticut are working to find better ways to vaccinate the elderly against the flu. The normal flu vaccine has a fairly high success rate in the general population, but it’s not as good at protecting people over 65 against influenza.

A normal dose of the flu vaccine has 15 micrograms of antigen, and that amount is good enough to protect the majority of the population against the flu. However, Dr. George Kuchel, the Citicorp Chair in Geriatrics and Gerentology at the University of Connecticut, is investigating a new, higher dose dose vaccine that seems to better at vaccinating the elderly.

“Recently, a new form of the flu vaccine came on the market which is the high dose flu vaccine,” Kuchel said. “It’s the same as the regular vaccine, except it has four times the amount of antigen or protein in it, so it’s a much more potent stimulus.”

Credit Peter Morenus / University of Connecticut
/
University of Connecticut
Dr. George Kuchel

A study published last year in The New England Journal of Medicine included more than 30,000 participants, and provided strong evidence that the high-dose vaccine provides better protection against influenza for elderly patients.

Kuchel is in the second year of a five-year clinical trial looking to build on those results. This particular study is smaller -- it will include about 100 participants each year. Along with giving participants one of the vaccines, Kuchel and his collaborators will analyze participants blood for levels and ratios of certain biomarkers.

Kuchel wants to use those biomarkers, as well as other patient information, to find ways to test which elderly patients should receive the high-dose vaccine, and which will do just as well on the normal one.

“These types of tests are exactly designed to address differences in terms of personalized or precision medicine, and to better understand who are the older adults who truly benefit from and require the high dose vaccine as opposed to the regular vaccine,” he said.  

The study is ongoing, and will enroll participants for this coming year beginning in early September.

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Related Content